Compare Cardinal Health Inc (CAH) vs Manchester United PLC (MANU) Price & Performance

Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.

Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.

Manchester United (MANU) trades at $21.70, up 0.32% on the day, with a bearish technical signal but improving fundamentals. Recent Q1 2026 earnings beat expectations, though the company remains unprofitable with a net income margin of -2.65%. Key developments include securing land for a new 100,000-seat stadium and Champions League qualification, which may boost future revenue.

The outlook is mixed: operational improvements and stadium plans offer long-term growth potential, but persistent losses, high debt, and weak cash conversion pose risks. Analyst sentiment is cautious with 40% buy ratings. Investors should weigh recovery prospects against financial stability concerns.